s research team are currently collaborating with several oncologists, dermatology pathologists, and surgeons at McGill University Health Center and the Jewish General Hospital in Montreal to confirm whether genetic alterations in NF1 affect how melanoma patients respond to immune checkpoint treatments. Dr. Watson presente